Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,077

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

The LKB1 tumor suppressor negatively regulates mTOR signaling

Open access
Shaw, Reuben J, Bardeesy, Nabeel, Manning, Brendan D, Lopez, Lyle, Kosmatka, Monica, DePinho, Ronald A, Cantley, Lewis C·2004·Cancer Cell
DOI 10.1016/j.ccr.2004.06.007
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2004.06.007

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 52

  1. Baas, 2004, Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD, Cell, 116, 457, 10.1016/S0092-8674(04)00114-X · DOI · Paper page
  2. Bardeesy, 2002, Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation, Nature, 419, 162, 10.1038/nature01045 · DOI · Paper page
  3. Boudeau, 2003, LKB1, a protein kinase regulating cell proliferation and polarity, FEBS Lett., 546, 159, 10.1016/S0014-5793(03)00642-2 · DOI
  4. Brugarolas, 2003, TSC2 regulates VEGF through mTOR-dependent and -independent pathways, Cancer Cell, 4, 147, 10.1016/S1535-6108(03)00187-9 · DOI · Paper page
  5. Cantley, 1999, New insights into tumor suppression, Proc. Natl. Acad. Sci. USA, 96, 4240, 10.1073/pnas.96.8.4240 · DOI · Paper page
  6. Carretero, 2004, Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene, Oncogene, 13, 4037, 10.1038/sj.onc.1207502 · DOI
  7. Cheng, 2004, Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status, J. Biol. Chem., 279, 15719, 10.1074/jbc.C300534200 · DOI · Paper page
  8. Crute, 1998, Functional domains of the α1 catalytic subunit of the AMP-activated protein kinase, J. Biol. Chem., 273, 35347, 10.1074/jbc.273.52.35347 · DOI · Paper page
  9. Dennis, 2001, Mammalian TOR, Science, 294, 1102, 10.1126/science.1063518 · DOI · Paper page
  10. Devroede, 1988, Colonic hamartomas in tuberous sclerosis, Gastroenterology, 94, 182, 10.1016/0016-5085(88)90628-2 · DOI
  11. Duan, 1999, Insulin-like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidylinositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway, J. Biol. Chem., 274, 37147, 10.1074/jbc.274.52.37147 · DOI
  12. El-Hashemite, 2003, Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin, Cancer Res., 63, 5173
  13. Entius, 2001, Molecular genetic alterations in hamartomatous polyps and carcinomas of patients with Peutz-Jeghers syndrome, J. Clin. Pathol., 54, 126, 10.1136/jcp.54.2.126 · DOI
  14. Fingar, 2004, Target of rapamycin (TOR), Oncogene, 23, 3151, 10.1038/sj.onc.1207542 · DOI · Paper page
  15. Fingar, 2002, Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E, Genes Dev., 16, 1472, 10.1101/gad.995802 · DOI · Paper page
  16. Garami, 2003, Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2, Mol. Cell, 11, 1457, 10.1016/S1097-2765(03)00220-X · DOI · Paper page
  17. Gomez, M.R., Sampson, J.R., and Whittemore, V.H. (1999). Tuberous Sclerosis, 3rd ed. (New York: Oxford University Press). · DOI
  18. Hardie, 2003, Management of cellular energy by the AMP-activated protein kinase system, FEBS Lett., 546, 113, 10.1016/S0014-5793(03)00560-X · DOI
  19. Harris, T.E., and Lawrence, J.C., Jr. (2003). TOR signaling. Sci STKE 2003, re15. · DOI
  20. Hawley, 2003, Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade, J. Biol., 2, 28, 10.1186/1475-4924-2-28 · DOI
  21. Hemminki, 1997, Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis, Nat. Genet., 15, 87, 10.1038/ng0197-87 · DOI · Paper page
  22. Huang, 2003, Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1), Mol. Cell, 11, 1491, 10.1016/S1097-2765(03)00180-1 · DOI
  23. Inoki, 2003, TSC2 mediates cellular energy response to control cell growth and survival, Cell, 115, 577, 10.1016/S0092-8674(03)00929-2 · DOI · Paper page
  24. Jishage, 2002, Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis, Proc. Natl. Acad. Sci. USA, 99, 8903, 10.1073/pnas.122254599 · DOI
  25. Jaeschke, 2002, Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent, J. Cell Biol., 159, 217, 10.1083/jcb.jcb.200206108 · DOI
  26. Kemp, 2003, AMP-activated protein kinase, super metabolic regulator, Biochem. Soc. Trans., 31, 162, 10.1042/bst0310162 · DOI · Paper page
  27. Kenerson, 2002, Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors, Cancer Res., 62, 5645
  28. Kwiatkowski, 2002, A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in TSC1 null cells, Hum. Mol. Genet., 11, 525, 10.1093/hmg/11.5.525 · DOI · Paper page
  29. Kwon, 2003, mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo, Proc. Natl. Acad. Sci. USA, 100, 12923, 10.1073/pnas.2132711100 · DOI · Paper page
  30. Manning, 2003, United at last, Biochem. Soc. Trans., 31, 573, 10.1042/bst0310573 · DOI
  31. Manning, 2002, Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway, Mol. Cell, 10, 151, 10.1016/S1097-2765(02)00568-3 · DOI · Paper page
  32. Martin, 2003, A role for Drosophila LKB1 in anterior-posterior axis formation and epithelial polarity, Nature, 421, 379, 10.1038/nature01296 · DOI · Paper page
  33. Miyoshi, 2002, Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice, Cancer Res., 62, 2261
  34. Neshat, 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc. Natl. Acad. Sci. USA, 98, 10314, 10.1073/pnas.171076798 · DOI · Paper page
  35. Onda, 2002, TSC2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway, Mol. Cell. Neurosci., 21, 561, 10.1006/mcne.2002.1184 · DOI
  36. Ossipova, 2003, LKB1 (XEEK1) regulates Wnt signalling in vertebrate development, Nat. Cell Biol., 5, 889, 10.1038/ncb1048 · DOI
  37. Podsypanina, 2001, An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/− mice, Proc. Natl. Acad. Sci. USA, 98, 10320, 10.1073/pnas.171060098 · DOI · Paper page
  38. Rajasekhar, 2003, Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes, Mol. Cell, 12, 889, 10.1016/S1097-2765(03)00395-2 · DOI · Paper page
  39. Ramaswamy, 1999, Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway, Proc. Natl. Acad. Sci. USA, 96, 2110, 10.1073/pnas.96.5.2110 · DOI · Paper page
  40. Rossi, 2002, Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis, Proc. Natl. Acad. Sci. USA, 99, 12327, 10.1073/pnas.192301399 · DOI
  41. Sanchez-Cespedes, 2002, Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung, Cancer Res., 62, 3659
  42. Shamji, 2003, Integration of growth factor and nutrient signaling, Mol. Cell, 12, 271, 10.1016/j.molcel.2003.08.016 · DOI
  43. Shi, 2002, Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779, Cancer Res., 62, 5027
  44. Stambolic, 1998, Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN, Cell, 95, 29, 10.1016/S0092-8674(00)81780-8 · DOI · Paper page
  45. Stein, 2000, The regulation of AMP-activated protein kinase by phosphorylation, Biochem. J., 345, 437, 10.1042/0264-6021:3450437 · DOI · Paper page
  46. Sun, 1999, PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5-triphosphate and Akt/protein kinase B signaling pathway, Proc. Natl. Acad. Sci. USA, 96, 6199, 10.1073/pnas.96.11.6199 · DOI · Paper page
  47. Tiainen, 1999, Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest, Proc. Natl. Acad. Sci. USA, 96, 9248, 10.1073/pnas.96.16.9248 · DOI · Paper page
  48. Viollet, 2003, The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity, J. Clin. Invest., 111, 91, 10.1172/JCI16567 · DOI · Paper page
  49. Wang, 1999, Allelic imbalance at the LKB1 (STK11) locus in tumours from patients with Peutz-Jeghers' syndrome provides evidence for a hamartoma-(adenoma)-carcinoma sequence, J. Pathol., 188, 9, 10.1002/(SICI)1096-9896(199905)188:1<9::AID-PATH326>3.0.CO;2-E · DOI
  50. Watts, 2000, The C. elegans par-4 gene encodes a putative serine-threonine kinase required for establishing embryonic asymmetry, Development, 127, 1467, 10.1242/dev.127.7.1467 · DOI
  51. Ylikorkala, 2001, Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice, Science, 293, 1323, 10.1126/science.1062074 · DOI · Paper page
  52. Zhang, 2003, Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR, J. Clin. Invest., 112, 1223, 10.1172/JCI200317222 · DOI

Cited by

Metadata

Authors
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2004-07
Volume
6
Issue
1
Pages
91-99
ISSN
1535-6108 (ISSN-L)
DOI
10.1016/j.ccr.2004.06.007
OpenAlex
W1992257057
Cited by
1,077
References
9
FWCI
19.35
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.